Markets:

Overview

News

Currencies

International

Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

72.83 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts ↗

August 06, 2024

Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped.

Via Investor's Business Daily

Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82 ↗

August 06, 2024

On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82.

Via Investor's Business Daily

NASDAQ:HALO is probably undervalued for the fundamentals it is displaying. ↗

August 05, 2024

When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Via Chartmill

3 Biotech Stocks on Track for 50% Returns (or More) by 2028 ↗

August 04, 2024

Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028!

Via InvestorPlace

(HALO) - Analyzing Halozyme Therapeutics's Short Interest ↗

August 01, 2024

Via Benzinga

Analyst Scoreboard: 14 Ratings For Halozyme Therapeutics ↗

August 01, 2024

Via Benzinga

Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective. ↗

July 22, 2024

There are signs that NASDAQ:HALO may be ready to breakout.

Via Chartmill

NASDAQ:HALO is showing good growth, while it is not too expensive. ↗

July 18, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is not too expensive for the growth it is showing.

Via Chartmill

What 13 Analyst Ratings Have To Say About Halozyme Therapeutics ↗

July 16, 2024

Via Benzinga

Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark ↗

July 26, 2024

On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier.

Via Investor's Business Daily

Beam Therapeutics Stock Earns RS Rating Jump To 85 ↗

July 24, 2024

On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85.

Via Investor's Business Daily

3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition ↗

July 18, 2024

These biotech stocks have promising outlooks that will bring major fortune to investors. Buy before it is too late.

Via InvestorPlace

Biotech Arvinas Stock Earns 82 RS Rating ↗

July 17, 2024

The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82.

Via Investor's Business Daily

Denali Therapeutics Stock Gets Technical Rating Upgrade ↗

July 16, 2024

Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Via Investor's Business Daily

3 Biotech Stocks to Buy Now: Q3 Edition ↗

July 15, 2024

Biotech stocks to buy can be a strong portfolio addition due to their capability for rapid growth within an evolving industry.

Via InvestorPlace

NASDAQ:HALO qualifies as a high growth stock and is consolidating. ↗

July 15, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO): a strong growth stock preparing for the next leg up?.

Via Chartmill

NASDAQ:HALO Shows Potential for a Breakout. ↗

July 09, 2024

Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective.

Via Chartmill

Decoding 12 Analyst Evaluations For Halozyme Therapeutics ↗

June 24, 2024

Via Benzinga

NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals. ↗

July 12, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is probably undervalued for the fundamentals it is displaying.

Via Chartmill

3 Highly Rated Biotech Stocks for Your July Buy List ↗

July 05, 2024

Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street.

Via InvestorPlace

3 Breakout Biotech Stocks on Track to Double by 2032 ↗

July 01, 2024

The tech sector has been at the forefront of the market rally in 2024. Consider these breakout biotech stocks as a great way to diversify.

Via InvestorPlace

UroGen Pharma Stock Earns 91 RS Rating ↗

June 27, 2024

UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier.

Via Investor's Business Daily

Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation. ↗

June 26, 2024

Investors seeking growth at a reasonable cost should explore HALOZYME THERAPEUTICS INC (NASDAQ:HALO).

Via Chartmill

Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval ↗

June 24, 2024

Sarepta Therapeutics had its Relative Strength (RS) Rating upgraded to 95 Monday, up from 68 a day earlier.

Via Investor's Business Daily

NASDAQ:HALO: a strong growth stock preparing for the next leg up?. ↗

June 24, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout.

Via Chartmill

Arcellx Stock Earns Relative Strength Rating Upgrade ↗

June 21, 2024

One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83.

Via Investor's Business Daily

Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87 ↗

June 20, 2024

Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level.

Via Investor's Business Daily

Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag. ↗

June 19, 2024

In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals.

Via Chartmill

The 3 Best Healthcare Stocks to Buy in June 2024 ↗

June 15, 2024

Aging populations and changing lifestyles mean healthcare is a secular story that these best healthcare stocks to buy will capitalize on.

Via InvestorPlace

Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans ↗

June 14, 2024

Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas.

Via Investor's Business Daily

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

All News about Halozyme Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today